Trials / Terminated
TerminatedNCT00696787
A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desvenlafaxine Sustained Release (DVS SR) | |
| DRUG | Lyrica® (Pregabalin) | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-06-13
- Last updated
- 2013-02-25
- Results posted
- 2010-02-23
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00696787. Inclusion in this directory is not an endorsement.